Target therapy in metastatic pheochromocytoma: current perspectives and controversies
Most of the pheochromocytomas (PCCs) are benign neoplasms, but when they are malignant, they can be difficult to treat. Despite advances in diagnosis and imaging, it remains an untreatable tumor, when metastases develop. A deeper understanding of the alteration of the specific molecular pathways cau...
Main Authors: | Amrallah A. Mohammed, Ayman M. El-Shentenawy, Mohamed A. Sherisher, Hani M. El-Khatib |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2014-09-01
|
Series: | Oncology Reviews |
Subjects: | |
Online Access: | http://www.oncologyreviews.org/index.php/or/article/view/249 |
Similar Items
-
Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas
by: Camilo Jimenez, et al.
Published: (2020-08-01) -
Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma—Case Report and Review of the Literature
by: Anli Tong, et al.
Published: (2020-02-01) -
Hemodynamic instability during percutaneous ablation of extra-adrenal metastases of pheochromocytoma and paragangliomas: a case series
by: Atousa Deljou, et al.
Published: (2018-11-01) -
Reactive Oxygen Species: A Promising Therapeutic Target for <i>SDHx</i>-Mutated Pheochromocytoma and Paraganglioma
by: Katerina Hadrava Vanova, et al.
Published: (2021-07-01) -
Metastatic pheochromocytoma in an 18-year-old
by: Ali Cadili, et al.
Published: (2016-03-01)